Divalproex
Indications
Divalproex sodium is a stable 1:1 coordination compound of sodium valproate and valproic acid that dissociates to valproate ion in the gut. It is one of the broadest-spectrum antiseizure medications available and is also approved for acute mania in bipolar disorder and for migraine prophylaxis in adults. The drug’s wide efficacy is matched by an unusually heavy adverse-effect profile — three FDA boxed warnings (hepatotoxicity, fetal risk, pancreatitis), a strong dose-dependent teratogenicity signal, and clinically important pharmacokinetic interactions — so prescribing decisions require a careful weighing of indication against alternatives, particularly in women of childbearing potential.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Complex partial (focal) seizures | Adults & children ≥10 y | Monotherapy or adjunctive | FDA Approved |
| Simple & complex absence seizures | Adults & children | Monotherapy or adjunctive | FDA Approved |
| Multiple seizure types including absence | Adults & children | Adjunctive | FDA Approved |
| Acute manic or mixed episodes of bipolar I disorder | Adults | Monotherapy or adjunctive | FDA Approved |
| Migraine prophylaxis | Adults | Prevention | FDA Approved |
Divalproex is widely viewed as a first-line option for idiopathic generalised epilepsies (juvenile myoclonic epilepsy, generalised tonic–clonic seizures, absence syndromes) — but with strict reservations in patients of reproductive potential. The 2018 EURAP analysis (Tomson et al., Lancet Neurol) confirmed that valproate carries the highest rate of major congenital malformations among the eight commonly used antiseizure drugs studied, and the risk is steeply dose-dependent. Modern guideline practice (NICE NG217, AAN, ILAE) therefore favours lamotrigine, levetiracetam, or other alternatives in women of childbearing potential whenever clinically reasonable.
Bipolar maintenance therapy (high evidence): 750–2000 mg/day to maintain trough 50–125 mcg/mL — supported by APA and CANMAT/ISBD bipolar guidelines as a maintenance option, particularly in patients who responded to valproate during an acute episode.
Status epilepticus, second-line (high evidence): IV valproate 20–40 mg/kg over 10 minutes (uses the IV sodium valproate product, not divalproex itself) — endorsed by the AES 2016 status epilepticus guideline as an alternative to fosphenytoin or levetiracetam.
Schizoaffective disorder, adjunctive (moderate evidence): Used for mood stabilisation in the manic-spectrum subtype, alongside antipsychotic therapy.
Agitation/aggression in dementia or traumatic brain injury (low evidence): Not recommended as routine therapy; meta-analyses have not shown consistent benefit and the safety profile is unfavourable in older adults.
Cluster headache prophylaxis (low evidence): Anecdotal use for chronic cluster headache; not endorsed as first-line.
Dosing
Divalproex dosing is anchored to clinical scenario, target serum concentration (50–100 mcg/mL is the standard therapeutic range; 100–125 mcg/mL may be acceptable in refractory mania or epilepsy), and the formulation chosen. Delayed-release tablets (Depakote DR) are dosed twice daily; extended-release tablets (Depakote ER) are dosed once daily but provide ~10–20% lower bioavailability — so the ER total daily dose is typically 8–20% higher than the equivalent DR dose to maintain the same trough.
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Focal or generalised epilepsy, monotherapy | 10–15 mg/kg/day in 1–2 divided doses | Increase by 5–10 mg/kg/wk to clinical effect | 60 mg/kg/day | Target trough 50–100 mcg/mL DR: BID dosing · ER: once daily, raise total daily dose ~8–20% |
| Acute mania (bipolar I) | 750 mg/day in divided doses (DR) or 25 mg/kg/day once daily (ER) | Titrate rapidly to clinical effect & trough 50–125 mcg/mL | 60 mg/kg/day | Loading-dose protocols (20–30 mg/kg over 1–2 days) used in inpatient settings Faster response than lithium for acute mania |
| Bipolar maintenance | Continue acute-phase dose | Lowest dose maintaining euthymia and trough 50–100 mcg/mL | 60 mg/kg/day | Reassess need annually; consider taper if euthymic ≥2 years on monotherapy Withdraw slowly to reduce relapse risk |
| Migraine prophylaxis (Depakote DR) | 250 mg PO BID | 500–1000 mg/day, divided | 1000 mg/day | Assess response over 8–12 weeks before declaring failure Contraindicated in pregnancy |
| Migraine prophylaxis (Depakote ER) | 500 mg PO once daily × 1 week | 1000 mg PO once daily | 1000 mg/day | ER preferred for adherence at this dose Listed as Level A migraine preventive in AAN/AHS guidance |
| Status epilepticus, second-line (IV valproate, off-label) | 20–40 mg/kg IV over 10 minutes | Continuous infusion 1–4 mg/kg/h or 5 mg/kg q6h IV | 40 mg/kg load | Uses sodium valproate IV — divalproex itself has no IV form AES 2016 guideline alternative to fosphenytoin/levetiracetam |
| Older adults (epilepsy or mania) | 10 mg/kg/day or 250 mg BID | Titrate slowly; aim for lowest effective trough | As tolerated | Higher risk of somnolence, confusion, hyperammonaemia, and fluid & nutritional deficits Check ammonia for any unexplained encephalopathy |
Pediatric Dosing (Epilepsy)
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Children ≥10 years (focal or generalised epilepsy) | 10–15 mg/kg/day divided BID | Increase by 5–10 mg/kg/wk to effect | 60 mg/kg/day | Sprinkle capsule useful for children unable to swallow tablets Sprinkle on soft food; do not chew |
| Children 2–10 years | 15–20 mg/kg/day divided | Higher mg/kg often needed than in adults | 60 mg/kg/day | Faster clearance than in adults; trough monitoring guides dose Avoid polytherapy where possible |
| Children <2 years | Use only as monotherapy and only when alternatives are inadequate | Markedly elevated risk of fatal hepatotoxicity (boxed warning) Contraindicated in known mitochondrial disorders due to POLG mutations | ||
Adjustment in Special Populations
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hepatic impairment | Contraindicated in significant hepatic disease | If history of mild hepatic disease without active dysfunction, individualised dosing with intensive monitoring Free valproate level useful | ||
| Renal impairment | Standard dose | Standard dose | Standard maximum | Free fraction may rise in uraemia; total levels can be misleading Check free valproate if symptomatic |
| Pregnancy (for epilepsy or bipolar; NEVER for migraine) | Avoid; switch to alternative pre-conception | If unavoidable, lowest effective dose | Aim <700 mg/day if used | EURAP 2018 dose-MCM rates: ~6% at <650 mg/day, ~10% at 650–1450 mg/day, ~24% at >1450 mg/day. Folate 4–5 mg/day; vitamin K at term Free valproate rises across pregnancy |
| Hypoalbuminaemia (cirrhosis, malnutrition, critical illness) | Standard dose | Standard dose | Standard maximum | Total level under-represents free fraction; check free valproate Aspirin or warfarin worsens displacement |
Check a trough valproate level after 3–5 days at a steady dose. The standard target range is 50–100 mcg/mL for epilepsy and 50–125 mcg/mL for mania. Free valproate (normal 5–10 mcg/mL) becomes the more reliable marker in pregnancy, hypoalbuminaemia, renal failure, or when concurrent salicylate or warfarin therapy is in play, because the saturable albumin binding of valproate means total levels can stay within range even as the free fraction rises into toxic territory.
Depakote ER provides approximately 80–90% of the bioavailability of Depakote DR on a milligram-for-milligram basis. When converting from DR to ER, raise the total daily dose by 8–20% (e.g. DR 1000 mg/day → ER 1000–1250 mg/day) and recheck a trough level after 7 days. The ER formulation has flatter peak-to-trough fluctuation, often improving tolerability of dose-related side effects (tremor, GI upset).
Pharmacology
Mechanism of Action
Valproate’s antiseizure and mood-stabilising effects arise from several complementary mechanisms rather than a single dominant target. It enhances γ-aminobutyric acid (GABA) signalling — by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase and by upregulating glutamic acid decarboxylase — and so raises synaptic GABA. It produces use-dependent blockade of voltage-gated sodium channels (similar to phenytoin and carbamazepine) and modulates T-type calcium currents in thalamic neurons, an effect thought to underlie its particular efficacy against absence seizures. At higher concentrations valproate inhibits histone deacetylases and reduces NMDA-receptor signalling — mechanisms implicated in both its mood-stabilising activity and its teratogenic effects on neural-tube and neurodevelopmental programmes. The migraine-prophylactic mechanism is incompletely characterised but is presumed to involve reduced cortical hyperexcitability and modulation of trigeminal nociception.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~90% (DR); ER ~80–90% relative to DR; Tmax ≈4 h (DR), 7–14 h (ER); food delays but does not reduce absorption | Take with food to reduce GI upset; ER once-daily dosing improves adherence and flattens peak-related side effects |
| Distribution | Vd ~0.1–0.4 L/kg; protein binding 80–90% (mostly albumin), saturable above ~70–80 mcg/mL — free fraction rises sharply at higher concentrations and in hypoalbuminaemia | Total trough levels can mislead in pregnancy, renal failure, cirrhosis, or with aspirin/warfarin co-therapy; check free valproate when discrepancy suspected |
| Metabolism | Hepatic, multi-pathway: glucuronidation (~50%), mitochondrial β-oxidation (~40%), CYP2C9/2A6/2B6 ω-oxidation (~10%); produces 4-en-VPA metabolite implicated in hepatotoxicity | Strong enzyme inducers (rifampin, phenytoin, carbamazepine) substantially reduce levels; valproate itself inhibits glucuronidation (raises lamotrigine) and CYP2C9 (raises phenytoin free fraction) |
| Elimination | Plasma t½ 9–16 h in adults (shorter in children, longer in neonates); <3% excreted unchanged in urine; remainder as glucuronide and oxidative metabolites | Renal impairment does not require dose adjustment; haemodialysis only modestly removes valproate at therapeutic concentrations but is effective in massive overdose |
Therapeutic concentrations: 50–100 mcg/mL covers most epilepsy responders; 50–125 mcg/mL is acceptable in refractory disease and in acute mania. Hyperammonaemia can occur at any concentration but becomes more likely above 100 mcg/mL and with concomitant topiramate, carnitine deficiency, or unrecognised heterozygous urea-cycle defects. Toxicity above 175 mcg/mL is associated with stupor, coma, cerebral oedema, and pancreatitis.
Side Effects
Frequency figures below are drawn predominantly from the FDA-labelled adverse-reactions tables for the bipolar mania and adjunctive epilepsy trials. Some adverse effects (weight gain, alopecia, polycystic-ovary changes, cognitive teratogenicity) emerge with chronic exposure rather than in short trials and so appear under-represented in registration data.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | ~15–31% (highest in mania trials) | Usually transient; take with food and consider ER formulation |
| Somnolence | ~19–27% | Dose-related; warn before driving until stable on dose |
| Dizziness | ~18–25% | Usually settles within weeks; consider dose splitting |
| Tremor (postural / fine) | ~10–25% (dose-related) | More prominent at troughs >100 mcg/mL; β-blocker (propranolol) effective if intolerable |
| Headache | ~15–31% | Usually mild; consider rebound from sub-therapeutic level if severe |
| Vomiting | ~7–23% | Persistent vomiting + abdominal pain is a red flag for pancreatitis or hepatotoxicity |
| Asthenia / fatigue | ~7–21% | Often improves with dose reduction; check thyroid and ammonia if persistent |
| Weight gain (chronic use) | ~10–58% over months–years | Median 4–10 kg over the first year; counsel before initiation in young women given metabolic and PCOS implications |
| Alopecia (chronic use) | ~7–24% | Often dose-related; selenium and zinc supplementation may help; usually reversible on withdrawal |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Thrombocytopenia (dose-related) | Asymptomatic in ~5–27% across trials; clinically significant in ~5% | Risk rises sharply at troughs >100 mcg/mL and in older adults; check before surgery |
| Asymptomatic hyperammonaemia | ~5–10% | Common and usually benign; relevant only when accompanied by encephalopathy |
| Diarrhoea / dyspepsia | ~7–13% | Often improves with ER formulation or food |
| Increased appetite | ~5–10% | Drives the chronic weight gain; counsel about portion control early |
| Peripheral oedema | ~1–8% | Usually mild; rule out hepatic and cardiac causes if marked |
| Mild transaminase elevation | ~5–10% | Asymptomatic 1–3× ULN rises are common and usually not clinically significant; values >3× ULN warrant pause and re-evaluation |
| Menstrual irregularity / PCOS-like syndrome | ~5–10% in young women | Higher with valproate than other antiseizure medications; ask specifically about menstrual regularity, hirsutism, acne |
| Confusion or cognitive slowing | ~3–7% | Usually dose-related; consider hyperammonaemia even with normal LFTs |
| Rash (non-serious) | ~1–6% | Generally mild; serious cutaneous reactions (SJS/TEN) are rare but reported |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe / fatal hepatotoxicity | Rare overall; substantially higher in children <2 y on polytherapy and in mitochondrial disease (POLG mutations) | First 6 months of treatment | Discontinue immediately for unexplained weakness, lethargy, anorexia, vomiting, jaundice, or LFTs >3× ULN; supportive care; sometimes irreversible despite withdrawal |
| Acute pancreatitis (including haemorrhagic) | Rare; case-series suggest ~1 per 100–500 patient-years; occasionally fatal | Anytime — shortly after initiation or after years | Discontinue; supportive care; check lipase/amylase for any new abdominal pain with vomiting or anorexia; avoid rechallenge |
| Major congenital malformations & lower IQ in offspring | ~10% MCM rate at typical doses (EURAP 2018); dose-dependent (24% at >1450 mg/day); mean IQ reduced ~7–10 points (NEAD) | First trimester (organogenesis); cognitive effects throughout | Avoid in women of childbearing potential where alternatives exist; if essential, lowest effective dose, folic acid 4–5 mg/day, formal pregnancy-prevention counselling |
| Hyperammonaemic encephalopathy | Uncommon (~1–2%); higher with topiramate co-therapy or unrecognised urea-cycle defect | Days to weeks of starting or dose increase | Check ammonia in any unexplained encephalopathy even with normal LFTs; reduce dose or stop; L-carnitine 100 mg/kg/day if severe |
| Severe thrombocytopenia / coagulopathy | ~1–5% with severe drops; risk rises at troughs >100 mcg/mL | Weeks to months | Reduce dose; check platelets, INR, fibrinogen; pause before surgery |
| Stevens-Johnson syndrome / toxic epidermal necrolysis | Very rare | First weeks of therapy | Permanent discontinuation; emergency dermatology referral |
| DRESS syndrome | Very rare | 2–8 weeks of starting | Permanent discontinuation; systemic corticosteroid; supportive care |
| Suicidal ideation (AED class warning) | ~1 in 500 vs placebo across antiseizure medications | First weeks; risk persists | Counsel patient and family; assess at each visit; provide crisis-line resources |
| Antiseizure-medication–related bone loss | Bone density falls modestly on chronic therapy | Months–years | Calcium 1000 mg + vitamin D 800 IU daily; periodic DEXA on long-term therapy |
| Hypothermia | Very rare; reported in adults & children | Anytime | Consider valproate as cause for unexplained core temperature <35 °C |
Discontinuation rates from the bipolar mania and migraine prophylaxis registration trials were modest, but real-world long-term tolerability is worse — chronic use is heavily limited by weight gain, alopecia, cognitive concerns, and contraceptive considerations in young women.
| Reason for Discontinuation | Approximate Rate | Context |
|---|---|---|
| GI intolerance (nausea, vomiting, dyspepsia) | ~3–5% | Often preventable by ER formulation and food |
| Weight gain | ~2–4% | Most common reason in chronic users, especially young women |
| Tremor / sedation | ~2–4% | Often dose-related; trial of dose reduction first |
| Hepatic enzyme elevation | ~1–2% | Most early rises are mild; severe rises require permanent withdrawal |
| Pregnancy or pre-conception planning | ~3–5% of women of childbearing potential | Switch to alternative AED before conception, ideally 6+ months in advance |
| Pancreatitis | <1% | Mandatory permanent discontinuation |
Valproate-induced hyperammonaemic encephalopathy can occur with normal liver function tests and at therapeutic drug levels. The presentation is unexplained lethargy, confusion, ataxia, or new EEG slowing — sometimes mistaken for a worsening seizure disorder or dementia. Always check ammonia in patients on valproate who develop new neurocognitive change, particularly when topiramate is co-prescribed, after a dose increase, in older adults, in carriers of urea-cycle defects, or in patients with low carnitine. Reducing or stopping valproate and considering L-carnitine (100 mg/kg/day, max 6 g/day) usually reverses the picture within days.
Drug Interactions
Valproate has one of the most complex interaction profiles among antiseizure medications. It is a substrate of multiple metabolic pathways (glucuronidation, β-oxidation, CYPs), an inhibitor of UGT and CYP2C9, and is 80–90% protein-bound — so both pharmacokinetic and protein-binding interactions are common. Two interactions are clinically critical and warrant proactive intervention: carbapenem antibiotics and lamotrigine.
Monitoring
Therapeutic drug monitoring is a core part of safe valproate prescribing. Levels are typically checked as a trough (immediately before next dose) once steady state has been reached (3–5 days). Liver and haematology tests should be performed before initiation and periodically thereafter, with extra vigilance during the first six months when serious hepatotoxicity is most likely. Symptom-driven testing (ammonia, lipase, free valproate) is at least as important as protocol-driven testing.
-
Trough valproate level
Day 3–5 after start or dose change; then every 3–6 months
Routine Target 50–100 mcg/mL (epilepsy) or 50–125 mcg/mL (mania). Repeat after any added/stopped interacting medication or significant illness. -
LFTs (ALT, AST, bilirubin)
Baseline; every 2–4 weeks for first 6 months; then every 3–6 months
Routine Stop drug for transaminases >3× ULN or any clinical features of hepatic dysfunction (malaise, anorexia, jaundice). Most fatal hepatotoxicity occurs in the first 6 months. -
CBC (platelets, WBC)
Baseline; every 3–6 months; before any planned surgery
Routine Thrombocytopenia is dose-related. Hold or reduce dose if platelets <100 ×10⁹/L; consider alternatives if <75 ×10⁹/L. -
Pregnancy test & contraception review
Before initiation in any woman of childbearing potential; at least annually thereafter
Routine Document pregnancy-prevention counselling and effective contraception in the chart at every visit. Many regulators (UK MHRA, EMA) require formal pregnancy-prevention programme enrolment. -
Weight, BMI, waist
Baseline; every visit
Routine Counsel proactively. Significant weight gain may justify a switch in young women given metabolic and PCOS implications. -
Mood / suicidality screen
Every visit
Routine Class warning applies to all antiseizure medications. Document direct enquiry; provide crisis resources. -
Free (unbound) valproate level
When clinically indicated
Trigger-based Check in pregnancy, hypoalbuminaemia, severe renal impairment, suspected toxicity with normal total levels, or on co-therapy with aspirin/warfarin. Normal range 5–10 mcg/mL. -
Serum ammonia
For any unexplained encephalopathy, lethargy, or new cognitive change
Trigger-based Free-flow venous sample on ice, prompt analysis. Levels >100 µmol/L with symptoms strongly suggest valproate-induced hyperammonaemic encephalopathy even with normal LFTs. -
Lipase / amylase
For any new abdominal pain, persistent vomiting, or anorexia
Trigger-based Pancreatitis can occur at any time and may be fatal. Discontinue permanently if confirmed; routine baseline screening is not required. -
Coagulation (PT/INR, fibrinogen)
Before any surgical procedure; if bruising/bleeding
Trigger-based Valproate can cause acquired von Willebrand-like defect, hypofibrinogenaemia, and platelet dysfunction in addition to thrombocytopenia. -
Bone density (DEXA)
Periodically on long-term therapy (≥5 y) or with risk factors
Trigger-based Consider calcium 1000 mg/day and vitamin D 800 IU/day for chronic users; weight-bearing exercise.
Contraindications & Cautions
Absolute Contraindications
- Hepatic disease or significant hepatic dysfunction. Per FDA labelling, divalproex must not be administered to patients with significant hepatic disease.
- Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG), e.g. Alpers-Huttenlocher syndrome — and suspected mitochondrial disease in any child <2 years.
- Known urea-cycle disorders (ornithine transcarbamylase deficiency, citrullinemia, etc.). Risk of fatal hyperammonaemic encephalopathy.
- Documented hypersensitivity to valproate or any excipient.
- Migraine prophylaxis in pregnancy. Fully contraindicated by FDA label; the migraine indication is not severe enough to justify the teratogenic risk.
Relative Contraindications (Specialist Input Recommended)
- Pregnancy or planning pregnancy — for any indication. Continue only if no acceptable alternative for epilepsy or bipolar disorder; document shared decision-making and informed consent.
- Children <2 years on polytherapy — markedly elevated risk of fatal hepatotoxicity; only justifiable as last-resort monotherapy for severe refractory seizures.
- Pre-existing thrombocytopenia or coagulopathy.
- Severe pancreatitis history, particularly drug-induced.
- Severe carnitine deficiency — increases risk of hepatotoxicity and hyperammonaemia.
Use with Caution
- Older adults — somnolence, dehydration, hyponatraemia, and tremor are common; start at low dose and titrate slowly.
- Concomitant carbapenems — see Drug Interactions; usually a hard avoid for patients with seizure or bipolar indication.
- Concomitant lamotrigine or topiramate — modify dose schedules and monitor closely.
- Hypoalbuminaemia, severe renal failure, advanced cirrhosis — total levels mislead; check free valproate.
- HIV/HTLV-1 infection — valproate may increase HIV replication in vitro; clinical significance uncertain but consider alternatives where reasonable.
- Cannabidiol co-therapy — additive hepatotoxicity risk; monitor LFTs carefully.
Hepatic failure resulting in fatalities has occurred in patients receiving valproate, usually during the first six months of treatment. Children under 2 years are at considerably increased risk, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by intellectual disability, and those with organic brain disease. In this group, divalproex should be used with extreme caution and as a sole agent. The benefits of therapy must be weighed against the risks. Patients with mitochondrial disease (POLG mutations, Alpers-Huttenlocher syndrome) are at especially high risk.
Serious or fatal hepatotoxicity may be preceded by non-specific symptoms — malaise, weakness, lethargy, facial oedema, anorexia, vomiting — and, in patients with epilepsy, by loss of seizure control. Patients should be monitored closely for these symptoms. LFTs should be performed before therapy and at frequent intervals thereafter, especially during the first six months. The drug should be discontinued immediately for any clinical suggestion of hepatic dysfunction.
Valproate can cause major congenital malformations, particularly neural-tube defects (e.g. spina bifida), as well as orofacial clefts, cardiac and limb malformations, and hypospadias. Maternal valproate use during pregnancy is also associated with decreased IQ scores in offspring (NEAD study, mean reduction 7–10 IQ points) and an increased risk of autism spectrum disorder.
Divalproex is contraindicated for migraine prophylaxis in pregnant women. For epilepsy or bipolar disorder, valproate should not be used in women of childbearing potential unless other treatments have failed to provide adequate seizure or symptom control or are otherwise unacceptable. In such cases, effective contraception is required, the lowest effective dose should be used, and folic acid 4–5 mg/day should be supplemented before and during pregnancy.
Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some cases have been described as haemorrhagic with rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated.
Patient Counselling
Purpose of Therapy
Explain that divalproex (Depakote) is used to control epilepsy, to stabilise mood in bipolar disorder, or to prevent migraine — depending on the patient’s diagnosis. Set expectations: the medicine often works well but has serious risks that need to be discussed openly, including liver injury, inflammation of the pancreas, and a high risk of harm to a baby if taken in pregnancy. The doctor will check blood tests at the start and at intervals afterwards, and the patient should report any new symptoms quickly rather than waiting for the next appointment.
How to Take
Delayed-release tablets (Depakote) are usually taken twice daily with food. Extended-release tablets (Depakote ER) are taken once daily, ideally at the same time each day. Tablets should be swallowed whole and not chewed or crushed. The sprinkle capsule can be opened and the contents sprinkled onto a small amount of soft food (e.g. apple sauce) and swallowed without chewing. If a dose is missed and remembered the same day, take it; if it is nearly time for the next dose, skip the missed one — never double up.
Sources
- U.S. Food and Drug Administration / DailyMed. Depakote (divalproex sodium) delayed-release tablets — current full prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=depakote Authoritative source for the three boxed warnings (hepatotoxicity, fetal risk, pancreatitis), contraindications, dosing, and adverse-reaction tables.
- U.S. Food and Drug Administration. Depakote ER (divalproex sodium) extended-release tablets — current full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021168s044lbl.pdf Once-daily extended-release product; same boxed warnings as DR plus formulation-specific dosing.
- UK Medicines & Healthcare products Regulatory Agency (MHRA). Valproate Pregnancy Prevention Programme — guidance for prescribers. https://www.gov.uk/drug-safety-update/valproate-pregnancy-prevention-programme Defines the formal pregnancy-prevention enrolment, annual risk-acknowledgment form, and contraception requirements that apply to women of childbearing potential in the UK.
- Tomson T, Battino D, Bonizzoni E, et al; EURAP Study Group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–538. doi:10.1016/S1474-4422(18)30107-8. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30107-8/fulltext Largest contemporary registry analysis: valproate carries the highest MCM rate (~10%) of the eight commonly used AEDs, with strong dose-dependence (~24% at >1450 mg/day vs ~6% at <650 mg/day).
- Tomson T, Battino D, Bonizzoni E, et al; EURAP Study Group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–617. PMID 21652013. https://pubmed.ncbi.nlm.nih.gov/21652013/ Established the dose–malformation relationship that anchors current “lowest effective dose” recommendations.
- Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–252. PMID 23352199. https://pubmed.ncbi.nlm.nih.gov/23352199/ Definitive prospective cognitive-outcomes study showing dose-dependent IQ reduction (mean ~7–10 points) in valproate-exposed children compared with carbamazepine, lamotrigine, and phenytoin exposure.
- Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;(10):CD010236. doi:10.1002/14651858.CD010236.pub2. Cochrane review confirming the consistent neurodevelopmental signal for in utero valproate exposure across multiple studies.
- Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61. doi:10.5698/1535-7597-16.1.48. AES 2016 guideline endorsing IV valproate (20–40 mg/kg) as a second-line option in convulsive status epilepticus.
- Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy — focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the AAN and the American Epilepsy Society. Neurology. 2009;73(2):133–141. AAN/AES practice parameter on antiseizure-drug selection in women of childbearing potential — still widely cited despite age.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline NG217. https://www.nice.org.uk/guidance/ng217 Current UK guidance on first-line antiseizure medication choice, including the strong restrictions on valproate use in women of childbearing potential.
- Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. Endorses divalproex as a first-line option for acute mania and as a maintenance option, with safety caveats for women of childbearing potential.
- Al-Quteimat O, Laila A. Valproate Interaction With Carbapenems: Review and Recommendations. Hosp Pharm. 2020;55(3):181–187. doi:10.1177/0018578719831974. PMC7243600. https://pmc.ncbi.nlm.nih.gov/articles/PMC7243600/ Comprehensive review confirming 50–90% reduction in valproate levels within 24–48 h of carbapenem co-administration, persistence 1–2 weeks after antibiotic discontinuation, and inability to overcome by dose escalation.
- U.S. National Library of Medicine. LactMed — Valproic Acid. https://www.ncbi.nlm.nih.gov/books/NBK501156/ Lactation-safety reference: low milk transfer; breastfeeding generally compatible with infant monitoring.